Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Resq Pharmaceuticals LLC has 1 pending office action located in the Biotechnology & Pharmaceuticals technology area. Prosecution is currently distributed across a distinct art unit and a distinct examiner. ALI S SAEED serves as the busiest examiner for the portfolio, responsible for the 1 pending action currently on record.
Because the portfolio's active prosecution involves only a distinct examiner, the company's current legal strategy is tied to the specific tendencies of ALI S SAEED. This narrow distribution across the art unit indicates a focused technical scope for the pending applications. Practitioners should focus on the past allowance rates of ALI S SAEED to gauge the likelihood of success for the outstanding matter currently under review. The absence of other pending cases means that this individual has a significant impact on the company's immediate intellectual property goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAEED, ALI S | 1 | 31.6% | +33.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18568440 | SUBCUTANEOUS FORMULATION AND METHODS FOR TREATING EDEMA REFRACTORY TO ORAL DIURETICS | SAEED, ALI S | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18568440 | SUBCUTANEOUS FORMULATION AND METHODS FOR TREATING EDEMA REFRACTORY TO ORAL DIURETICS | SAEED, ALI S | 1616 | §103DP | Non-Final OA | — | Pending | Dec 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialResq Pharmaceuticals LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ali S Saeed has the most, with 1 of Resq Pharmaceuticals LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
